Stelabid No 1 is used across therapeutic domains where both physical gastrointestinal symptoms and associated nervous tension contribute to patient distress. This combination acts as an agent that combines a smooth muscle relaxant and a nerve-calming agent, supporting a functional approach to symptom management.

---

Management of Functional Bowel Disorders

This medicine may be used across conditions presenting with acute episodes like Irritable Bowel Syndrome (IBS) and is relevant in conditions characterized by periods of heightened symptoms such as hyperacidity or gastritis. It helps address symptom clusters related to heightened physiological activity, including severe abdominal cramps, bloating, and functional diarrhea. This combined approach is applied during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.

Relief from Stress-Aggravated Symptoms

The approach combining symptomatic relief and central support is relevant in contexts marked by increased discomfort or tension, specifically for digestive symptoms that may be intensified by stress or anxiety. It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability during symptomatic periods.

---

Quick Facts: Symptomatic Support Domains

• Relief Focus: Supports general well-being by easing distress and contributing to improved comfort during symptomatic periods.
• Context of Use: Applied in scenarios where additional management of discomfort is required, especially when stress or anxiety triggers symptom flares.

Regulatory References

1. Health Canada Drug Product Database

Who Can and Cannot Use Stelabid No 1? — Official Regulatory Information

The eligibility profile for Stelabid No 1 is defined by absolute contraindications, age restrictions, and the patient's existing health status, as documented in official prescribing information.

Eligibility Scope

Population Status	Eligibility Classification (Example)
Populations for whom use is allowed	Adults with appropriate symptom profiles; Children 6 to 12 years (use established)
Populations for whom use is not recommended	Pregnant women (use may be unsafe); Breastfeeding women (components pass into milk)
Populations for whom use is contraindicated	Patients with known Phenothiazine allergy; Angle-closure glaucoma; Pyloric stenosis; Parkinson's disease; Blood dyscrasias; Severe liver damage

Age and Condition-Specific Eligibility

• Age-Related Rules: Children under 6 years are not established for use. In older adults, use is strictly prohibited in patients with dementia-related psychosis due to documented warnings for the drug class.
• Condition-Specific Rules: The medicine is contraindicated in conditions that may be worsened by its anticholinergic effect, such as prostatic hypertrophy or mechanical intestinal obstruction. Use requires caution in patients with a history of epilepsy or cardiovascular disease.
• Organ Impairment: Use is contraindicated in severe liver disease, while use in non-severe renal or hepatic impairment is subject to closer regulatory consideration.

Connection to the Overall Eligibility Profile

Official regulatory documents define patient eligibility by setting clear absolute contraindications for patients with specific systemic diseases (e.g., blood, liver, CNS status) and mechanical risks (e.g., glaucoma, obstruction). Eligibility is further restricted by age limitations and specific prohibitions for vulnerable groups, such as older adults with dementia-related psychosis, while requiring caution for cardiac and renal patients.

The official interaction profile of Stelabid No 1 reflects the combined effects of its two components, Isopropamide and Trifluoperazine. Regulatory information outlines specific interactions, including strictly prohibited combinations and alterations to systemic exposure.

---

Contraindicated and High-Risk Combinations

The phenothiazine component mandates that the medicine must not be co-administered with Adrenaline (Epinephrine), as this combination carries a risk of paradoxical hypotension. The drug is also contraindicated with other medicines known to prolong the QT interval (such as Pimozide or Sotalol) due to an additive cardiac risk. The combination with Desferrioxamine is restricted. Co-administration must be avoided with the contrast agent Metrizamide, requiring specific timing separation.

---

Pharmacodynamic Interactions

Co-administration with Central Nervous System (CNS) depressants, including alcohol, results in additive CNS depression, increasing sedation. Similarly, taking other anticholinergic agents concurrently leads to amplified anticholinergic effects. The drug may also cause pharmacodynamic antagonism, documented as reducing the intended therapeutic effect of Levodopa and certain antihypertensive agents.

---

Exposure and Metabolic Interactions

The absorption of Trifluoperazine is reduced by co-administration with aluminum hydroxide-containing antacids, which may lower plasma concentrations. The phenothiazine is metabolized through the CYP1A2 pathway, meaning inducers of this enzyme, such as smoking, may alter drug exposure. Regulatory documents note that elderly patients may exhibit heightened sensitivity to some of these pharmacodynamic effects.

Stelabid No 1 is a fixed-dose combination containing the two pharmacologically distinct agents, isopropamide and trifluoperazine, which exert effects on the autonomic and central nervous systems.

Isopropamide acts peripherally as a muscarinic acetylcholine receptor antagonist, particularly targeting receptors within the gastrointestinal (GI) tract smooth muscle. By blocking the binding of the endogenous neurotransmitter acetylcholine, it inhibits parasympathetic signaling to the enteric nervous system. The resultant reduction in smooth muscle contraction decreases GI tract motility and suppresses involuntary muscular spasms. Concurrently, it reduces glandular secretion, including gastric acid and other digestive fluids, by acting on glandular muscarinic receptors.

Trifluoperazine acts centrally as a typical antipsychotic, primarily functioning as a dopamine D2 receptor antagonist in the mesolimbic and mesocortical pathways of the brain. This antagonism modulates central dopaminergic neurotransmission. Trifluoperazine also exhibits antagonism at other receptors, including alpha-adrenergic, histamine H1, and serotonin 5- HT2 receptors, contributing to systemic effects, including modulation of the chemoreceptor trigger zone in the brainstem.

The combined actions result in a systemic physiological consequence of decreased smooth muscle hypermotility throughout the digestive tract and modulation of central dopaminergic and cholinergic signaling pathways.

How Stelabid No 1 is Used: Administration Guidelines

Stelabid No 1 is an Oral Tablet containing a fixed combination of Isopropamide 5 mg and Trifluoperazine 1 mg. Its administration protocol defines the standardized approach to use.

---

Standard Regimen and Frequency

The standard adult dosing regimen is one tablet taken twice daily (BID). This frequency ensures consistent therapeutic levels of both the anticholinergic and the low-dose phenothiazine components. The tablet may be administered with or without food.

Procedural Requirements

For proper administration, the tablet must be swallowed whole and should not be crushed or chewed, a requirement critical for maintaining the intended drug release. If a dose is missed, instructions specify not to take a double dose to compensate.

Duration and Population Constraints

The duration of use is typically restricted to short-term management. Continuous use of the Trifluoperazine component for non-psychotic conditions is often limited to 12 weeks.

Furthermore, a significant initial dose reduction (by at least half) is a mandatory principle for older adults or frail patients. Use in children under six years of age is generally not recommended.

Research evidence / Overview of studies for Stelabid No 1

Evidence for Functional Gastrointestinal Disorders with Spasms

The original research supporting the use of Stelabid No 1 was conducted using older clinical efficacy trials and controlled studies. This research was applied in studies examining patient-reported experiences related to conditions marked by functional limitations. Studies explored how symptoms change over time, focusing on outcomes related to physical discomfort, specifically in conditions characterized by fluctuating or episodic manifestations.

Research examined the drug’s role in influencing symptoms evaluated in trials, such as abdominal spasms, cramping, and functional diarrhea. Early clinical reports described patterns observed in the studies related to changes in the severity of these physical gut symptoms. The findings contribute to understanding symptom patterns in the broader evidence landscape of gastrointestinal distress.

Research on Nervous Tension and Associated Gut Symptoms

The combination was studied for its use in managing conditions involving periods of heightened symptoms that are associated with nervous tension. Research explored outcomes monitoring physiological strain or stress alongside physical symptoms, examining the dual-action approach. Studies focused on episodes where symptoms become more noticeable due to emotional factors.

Findings indicate that the drug was observed in some studies during research exploring short-term symptom changes related to the combined management of physical and central nervous system factors. Studies report how symptoms evolved in the observed populations when both the spasm component and the nervous tension component were addressed.

Long-term Clinical Use and Follow-up

Research describing the initial use of Stelabid No 1 primarily involved trials assessing short-term or episodic symptom patterns. The clinical trials used in the original regulatory review featured limited follow-up durations. Consequently, long-term effects are not fully established through modern efficacy trials.

The understanding of how the combination was evaluated over many months or years is largely drawn from observational settings evaluating daily-life functioning and long-standing clinical use. This evidence contributes to understanding symptom patterns in patients where symptoms may vary in intensity over time.

Research Evidence in Special Populations

The evidence base for Stelabid No 1 primarily describes adult patient populations diagnosed with functional gastrointestinal conditions. Research was applied in studies involving the general adult groups where symptoms were linked to functional imbalance.

However, data for certain groups remain insufficient. Specifically, research provides limited insight into outcomes related to specific geriatric cohorts or pediatric patients for this fixed-dose combination. Therefore, study results reflect the specific conditions and adult populations under which they were conducted.

What Remains Uncertain and Key Evidence Gaps

The certainty level is low when measured against modern clinical standards. A key limitation is the scarcity of recent, large-scale Randomized Controlled Trials (RCTs) focusing specifically on the fixed-dose combination of Isopropamide and Trifluoperazine. Much of the clinical information is derived from older trials and observational reports, which leads to variability in the research record.

Comparative evidence is lacking for how the drug was examined against newer single-agent or combination therapies currently available. Subgroup findings are uncertain, and there is limited information for long-term outcomes, particularly in defined functional GI subgroups. Research does not indicate whether an individual will respond similarly to the group patterns observed in these studies.

Common questions about Stelabid No 1 (FAQ)

---

Q: Can Stelabid No 1 be taken long-term for a chronic condition like IBS?

Official prescribing information indicates that for non-psychotic conditions, the use of the Trifluoperazine component is typically limited to a duration of 12 weeks. This time restriction is described to help mitigate the risk of developing persistent involuntary movements, known as Tardive Dyskinesia. Information regarding the use for chronic conditions suggests that periodic assessment may be involved.

---

Q: What is the official recommendation for stopping Stelabid No 1 treatment?

According to official product information, it is stated that the medication should not be stopped suddenly. Abrupt cessation may lead to withdrawal symptoms, which have been reported to include physical reactions such as dizziness, nausea, shaking, or muscle cramps. Changes to the duration of treatment are typically determined by a prescribing professional.

---

Q: Does Stelabid No 1 affect the ability to sweat or regulate body temperature?

Regulatory information indicates this medication can affect the body’s ability to control its temperature. This potential effect means that precautions against overheating in hot environments or excessive cooling in cold weather may be important.

---

Q: Is it possible to use Stelabid No 1 with other medications that cause drowsiness or sedation?

Official drug interaction guidelines state that taking Stelabid No 1 with other medications that cause sleepiness or sedation can result in additive Central Nervous System (CNS) depression. The combined effect leads to increased drowsiness, which is a factor considered during medical supervision. Examples of such medications include certain antihistamines or antidepressants.

---

Q: Are there specific over-the-counter pain relievers that interact with Stelabid No 1?

The regulatory safety profile indicates that the Trifluoperazine component may interact with certain types of nonsteroidal anti-inflammatory drugs (NSAIDs). Specific medications like Acetylsalicylic acid have been noted to potentially interact, possibly leading to an increased risk of hypertension.

---

Q: Does Stelabid No 1 interact with oral contraceptives?

Regulatory information reports that the Trifluoperazine component of Stelabid No 1 may interact with hormonal contraceptives or hormone replacement therapy.

---

Q: Does Stelabid No 1 affect hormone levels or cause breast enlargement or unexpected discharge?

Official side effect profiles note that the drug may cause an increase in the hormone prolactin, a condition known as hyperprolactinemia. This hormonal change can potentially lead to physical side effects such as breast swelling, discharge of milk from the nipples (lactation), or changes to the menstrual cycle.

---

Q: Does Stelabid No 1 treat stress, or just the stomach symptoms caused by stress?

Official documents state that Stelabid No 1 is used to relieve abdominal discomfort, cramps, and bloating that are linked to nervous tension or anxiety. The Trifluoperazine component itself is officially utilized in some cases for managing non-psychotic anxiety. The combination is designed to address both the physical spasm and the nervous factor.

---

Q: Why does Stelabid No 1 sometimes cause constipation?

Constipation is a reported side effect because the Isopropamide component is an anticholinergic agent. This class of medicine works by decreasing the movement (motility) of the gastrointestinal tract, which can slow down the passage of waste and lead to constipation.

---

Q: Can Stelabid No 1 cause problems with eye pressure or glaucoma?

The medication is formally contraindicated (strictly prohibited) for use in patients who have narrow-angle glaucoma. This is because the medication may interact with the pre-existing condition, potentially leading to increased eye pressure.

---

Q: Can Stelabid No 1 affect a person's blood cell count?

According to official safety information, the medication can lead to blood disorders, including low white blood cell levels (leukopenia) or bone marrow depression. The regulatory documents suggest that monitoring blood counts may be part of the therapeutic regimen.

---

Q: Can Stelabid No 1 affect blood sugar levels for patients with diabetes?

Official drug information suggests the medication may increase blood sugar levels. If changes in blood sugar occur, adjustments to the diabetes management plan may be considered.

---

Q: What is the risk of having a seizure while taking Stelabid No 1?

Regulatory documents state that this medication may lower the seizure threshold. This indicates that it could potentially make seizures more likely to occur, especially for individuals with pre-existing conditions or when taken with certain interacting drugs.

---

Q: Are stomach upset or nausea common when first starting Stelabid No 1?

Nausea is listed in the official documents as one of the common adverse effects reported with the use of this combination medicine.

---

Q: Is there a warning about sun sensitivity or sunburn while using Stelabid No 1?

Official warnings state that the Trifluoperazine component can increase the skin's sensitivity to the sun, a condition known as photosensitivity. The labeling suggests that protective measures, such as wearing sunscreen and protective clothing, may be necessary.

---

Q: Are there specific foods or drinks that should be avoided while taking Stelabid No 1?

Official interaction data advises against the concurrent consumption of alcohol due to the potential for severe additive drowsiness. It is also noted that the absorption of the Trifluoperazine component may be reduced when taken with aluminum hydroxide-containing antacids.

---

Q: Can Stelabid No 1 lead to uncontrolled movements, shaking, or muscle stiffness?

The drug can cause Extrapyramidal Symptoms (EPS), which involves movement-related effects. These include involuntary motor restlessness, muscle spasms (dystonia), and symptoms resembling Parkinson’s disease, such as tremors, rigidity, or a shuffling gait. These effects are associated with the phenothiazine component.

The official regulatory requirements for Stelabid No 1 tablets define specific environmental and handling constraints to ensure product stability.

Storage Requirements

The medication must be stored at a Controlled Room Temperature (CRT), maintained between 20 C and 25 C (68 F and 77 F). The tablets must be kept in the original, tightly closed container and protected from light. It is mandatory to keep this product out of the reach of children and to avoid freezing the medication.

Disposal Instructions

Disposal of unused or expired Stelabid No 1 should follow governmental guidance for non-controlled prescription drugs. The preferred method is to utilize an official drug take-back program when available. If a take-back program is not accessible, the product should be mixed with an undesirable substance (such as dirt or cat litter) and sealed in a bag before being placed in the household trash. Disposal into wastewater (flushing down the toilet or pouring down the sink) is generally discouraged for environmental protection.